Wockhardt receives ‘warning letter’ from USFDA for Waluj facility

20 Jul 2013 Evaluate

Wockhardt has received a ‘warning letter’ from USFDA for its Waluj facility, which lists the observations made during the inspection. The company has already initiated several corrective actions to resolve the same. The company continues to cooperate with USFDA to resolve the issues at the earliest. The company had earlier received an 'import alert' from USFDA on one of its manufacturing unit located in Waluj near Aurangabad on May 24, 2013.

Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.

Wockhardt Share Price

1477.30 16.15 (1.11%)
27-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1861.70
Dr. Reddys Lab 1389.35
Cipla 1506.15
Lupin 2228.00
Zydus Lifesciences 972.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.